Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568997 · ClinicalTrials.gov registry record
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
A clinical trial of Atopic Dermatitis, sponsored by Bausch Health Americas.
- Active
- Registry status
- 8,000
- Enrollment target
- 1
- Study location
NCT00568997 is a study of Atopic Dermatitis that is active but no longer recruiting, run by Bausch Health Americas. The registered enrollment target is 8,000 participants, above the 556-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (1339% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00568997, a study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Bausch Health Americas.
- ACTIVE NOT RECRUITING
- Registry status
- 8,000 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Conditions Studied
Interventions
- DRUG Pimecrolimus
Study Locations (1)
Pennsylvania
- Registry - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,000 participants |
| Start Date | 2005-06-27 |
| Est. Completion | 2028-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00568997
The ClinicalTrials.gov registry entry for NCT00568997 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 8,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 556-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (1339% higher). The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 1 intervention - of which Pimecrolimus is the first listed.
NCT00568997 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00568997 about?
NCT00568997 is a clinical study titled "10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus". This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
What is the current status of trial NCT00568997?
This trial is currently active not recruiting. The enrollment target is 8,000 participants. The study started on 2005-06-27. Estimated completion is 2028-06.
What conditions does trial NCT00568997 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT00568997?
The interventions under investigation include: Pimecrolimus (DRUG).
Who is sponsoring clinical trial NCT00568997?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568997 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry for Systemic Eczema Treatments
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
RECRUITING
-
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis
RECRUITING
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
RECRUITING · Phase 1
-
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.